PEN

Penumbra Inc

PEN, USA

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, and aspiration pump under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as detachable coils to treat patients with a wide range of neurovascular lesions under the Penumbra SMART COIL and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

https://www.penumbrainc.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
PEN
stock
PEN

Ozempic launched in India, priced at Rs 2,200 per week thefederal.com

Read more →
PEN
stock
PEN

Penumbra (PEN) Sees Upgraded Rating and Raised Price Target by C GuruFocus

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$306.7895

Analyst Picks

Strong Buy

12

Buy

2

Hold

4

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very Low

69.50

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very High

9.06

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

3.37 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

2.63 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

High

11.85 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.28

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 95.31% of the total shares of Penumbra Inc

1.

FMR Inc

(15.0193%)

since

2025/06/30

2.

BlackRock Inc

(10.8031%)

since

2025/06/30

3.

Vanguard Group Inc

(9.8993%)

since

2025/06/30

4.

T. Rowe Price Associates, Inc.

(3.5232%)

since

2025/06/30

5.

iShares Core S&P Mid-Cap ETF

(3.2322%)

since

2025/08/31

6.

State Street Corp

(3.002%)

since

2025/06/30

7.

Vanguard Total Stock Mkt Idx Inv

(2.9624%)

since

2025/07/31

8.

Fidelity Select Health Care

(2.8719%)

since

2025/07/31

9.

Fidelity Select Medical Tech and Devcs

(2.3718%)

since

2025/07/31

10.

Baillie Gifford & Co Limited.

(2.3645%)

since

2025/06/30

11.

Vanguard Small Cap Index

(2.2899%)

since

2025/07/31

12.

RTW INVESTMENTS, LLC

(2.2143%)

since

2025/06/30

13.

JPMorgan Chase & Co

(1.9253%)

since

2025/06/30

14.

Champlain Investment Partners, LLC

(1.907%)

since

2025/06/30

15.

Geode Capital Management, LLC

(1.8113%)

since

2025/06/30

16.

ClearBridge Advisors, LLC

(1.7915%)

since

2025/06/30

17.

Amvescap Plc.

(1.6244%)

since

2025/06/30

18.

Fidelity Advisor Health Care I

(1.6103%)

since

2025/07/31

19.

Strategic Advisers Fidelity US TtlStk

(1.609%)

since

2025/07/31

20.

T. Rowe Price Health Sciences

(1.5812%)

since

2025/07/31

21.

Capital World Investors

(1.3979%)

since

2025/06/30

22.

American Funds SMALLCAP World A

(1.393%)

since

2025/06/30

23.

HHG PLC

(1.362%)

since

2025/06/30

24.

Vanguard Small Cap Growth Index Inv

(1.29%)

since

2025/07/31

25.

Vanguard US Growth Investor

(1.2896%)

since

2025/06/30

26.

Morgan Stanley - Brokerage Accounts

(1.2784%)

since

2025/06/30

27.

Champlain Mid Cap Fund, LLC

(1.2273%)

since

2025/08/31

28.

Congress Asset Management Company, LLP

(1.1659%)

since

2025/06/30

29.

NORGES BANK

(1.1392%)

since

2025/06/30

30.

Vanguard Institutional Extnd Mkt Idx Tr

(1.0666%)

since

2025/07/31

31.

Baillie Gifford US Equity Growth

(1.008%)

since

2024/12/31

32.

JPMorgan Mid Cap Growth I

(0.9256%)

since

2025/07/31

33.

Vanguard Explorer Inv

(0.9083%)

since

2025/06/30

34.

AQR Capital Management LLC

(0.8487%)

since

2025/06/30

35.

Thrivent Financial For Lutherans

(0.8279%)

since

2025/06/30

36.

Allspring Global Investments Holdings, LLC

(0.8257%)

since

2025/06/30

37.

JPM US Mid Cap Growth-Composite

(0.7933%)

since

2025/06/30

38.

SPDR® S&P MIDCAP 400 ETF Trust

(0.7607%)

since

2025/07/31

39.

Invesco S&P MidCap Quality ETF

(0.7543%)

since

2025/08/29

40.

iShares Russell Mid-Cap Growth ETF

(0.6324%)

since

2025/08/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

1.12

Latest Release

Date

2025-09-30

EPS Actual

0.97

EPS Estimate

0.9265

EPS Difference

0.0435

Surprise Percent

4.6951%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(5.5)
Defensive
Highly Defensive(8)
Dividend
Weak Dividend Profile(3)
Economic Moat
Wide Moat Company(7.8)
GARP
Fair GARP(4.5)
Growth
Weak Growth Prospect(3)
Momentum
Moderate Momentum(4)
Net Net
Possible Net-Net(4)
Quality
High Quality(7.5)
Value
Fair Value(4.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.